Completed PHASE4 INTERVENTIONAL NCT00190736

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months); With a Brief Evaluation of Executive Cognition

Sponsor: Eli Lilly and Company

Conditions ADHD

Interventions Atomoxetine Hydrochloride placebo

Updated 6 times since 2017 Last updated: Nov 5, 2007 Started: Sep 30, 2004 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00190736, this PHASE4 trial focuses on ADHD and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boise, United States , Charlotte, United States , Clementon, United States , Farmington, United States , Hamden, United States , Herndon, United States , Houston, United States , Jacksonville, United States , Lafayette, United States , Lake Jackson, United States and 8 more locations